Completed PHASE3 INTERVENTIONAL 1-arm NCT00550680

A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia

Sponsor: Hoffmann-La Roche

Conditions Chronic Renal Anemia

Interventions Methoxy polyethylene glycol-epoetin beta

Updated 6 times since 2017 Last updated: Feb 29, 2016 Started: Jan 31, 2008 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Renal Anemia and is currently completed. Hoffmann-La Roche leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aigáleo, Greece , Athens, Greece , Corinthos, Greece , Daphni-athens, Greece , Ioannina, Greece , Kalamata, Greece , Kyparissía, Greece , Lamia, Greece , Larissa, Greece , Livadeia, Greece and 4 more locations